{"id":3948,"date":"2025-03-31T18:11:53","date_gmt":"2025-03-31T18:11:53","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/epoprostenol-txt\/"},"modified":"2025-03-31T18:11:53","modified_gmt":"2025-03-31T18:11:53","slug":"epoprostenol-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/epoprostenol-txt\/","title":{"rendered":"Epoprostenol.txt"},"content":{"rendered":"

Epoprostenol<\/h1>\n

CLINICAL USE <\/H3>
\nVasodilation and inhibition of platelet aggregation without prolonging bleeding timeAlternative to heparin in haemodialysis Treatment of peripheral vascular disease and pulmonary hypertension

DOSE IN NORMAL RENAL FUNCTION <\/H3>2\u201350 ng\/kg\/minute, adjusted according to responseDialysis anticoagulation: 4 ng\/kg\/minute starting 10\u201315 minutes before and continuing during dialysis via the arterial line, adjusted according to response (range: 0.5\u201312 ng\/kg\/minute)

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :352.5<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 40\u201390 (as drug + metabolites)<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.357\u20131.015<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u20136 minutes\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsIncreased hypotensive effect with \u2018acetate\u2019 dialysis

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>500 microgram vial with diluent provided gives solution of 10 micrograms\/mL. Can be diluted further

    Route <\/H4>IV or into blood supplying dialyser

    Rate of Administration <\/H4>Via CRIP

    Comments<\/H4>Complicated dosing schedule \u2013 check calculations carefullyInfusion rate may be calculated by the following formula:Dose rate (mL\/hr) Dosage (ng\/kg\/min) \u00d7 body wt (kg) \u00d7 60 Concentration of infusion (ng\/mL) (usually 10 000 ng\/mL)

    OTHER INFORMATION <\/H4>Monitor BP and heart rate. Reduce dose if patient becomes hypotensive. Cardiovascular effects cease 30 minutes after stopping the infusionSome patients may exhibit allergic reaction to buffer solution used to reconstitute epoprostenolSolution retains 90% potency for 12 hours after dilutionThe concentrated solution should be filtered using the filter provided in the pack
    \n","protected":false},"excerpt":{"rendered":"

    Epoprostenol CLINICAL USE Vasodilation and inhibition of platelet aggregation without<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3948","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3948"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3948\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}